Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae causing meningitis in Egypt, 1998-2003.

OBJECTIVES To determine the antimicrobial susceptibility and serotype distribution of 205 isolates of Streptococcus pneumoniae, collected from the CSF of meningitis patients identified between 1998-2003, during sentinel meningitis surveillance in Egypt. METHODS Antimicrobial susceptibility was evaluated against six antibiotics using disc diffusion and Etest methods. Serotyping was performed by latex agglutination and the Quellung test. RESULTS Forty-nine percent of all isolates were found to be non-susceptible to penicillin (46% intermediate, MIC range 0.12-1.0 mg/L; 3% resistant, MIC = 2.0 mg/L), and 6% of the isolates were non-susceptible to ceftriaxone (5% intermediate, MIC = 1.0 mg/L; 1.3% resistant, MIC >/= 2 mg/L). Resistance rates for tetracycline and trimethoprim/sulfamethoxazole were high (52 and 59.7%, respectively), but those for erythromycin and chloramphenicol were lower (11 and 9%, respectively). Five serotypes (6B, 1, 19A, 23F and 6A) accounted for 37% of the total isolates. Ten isolates (5%) were non-typeable. Overall, 29 and 42% of serotypes were represented in the 7- and 11-valent conjugate vaccines, respectively. However, vaccine coverage for children <2 years was 38 and 56% for the 7- and 11-valent, respectively. CONCLUSIONS Resistance to penicillin may be increasing among S. pneumoniae strains causing meningitis in Egypt, and a moderate proportion of these strains are not covered by current pneumococcal conjugate vaccines. In addition to intensifying education efforts about judicious use of antibiotics, laboratory-based surveillance for other forms of invasive pneumococcal disease, especially pneumonia, is needed before decisions can be made regarding the most effective vaccines for control of this disease in Egypt.

[1]  M. Leinonen,et al.  Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  C. Whitney,et al.  Clonal Distribution of Invasive Pneumococcal Isolatesfrom Children and Selected Adults in the United States Prior to7-Valent Conjugate VaccineIntroduction , 2003, Journal of Clinical Microbiology.

[3]  R. Heyderman,et al.  Rapid emergence of resistance to penicillin and trimethoprim-sulphamethoxazole in invasive Streptococcus pneumoniae in Zimbabwe. , 2003, International journal of antimicrobial agents.

[4]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[5]  G. Procop,et al.  Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals. , 2003, The Journal of antimicrobial chemotherapy.

[6]  D. Feikin,et al.  Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Eskola,et al.  Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. , 2001, The Journal of infectious diseases.

[8]  A. Ortqvist,et al.  Pneumococcal vaccination: current and future issues. , 2001, The European respiratory journal.

[9]  P. Rhomberg,et al.  Antimicrobial Resistance among Clinical Isolates ofStreptococcus pneumoniae in the United States during 1999–2000, Including a Comparison of Resistance Rates since 1994–1995 , 2001, Antimicrobial Agents and Chemotherapy.

[10]  A. Schuchat,et al.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. , 2001, JAMA.

[11]  S. Lockhart,et al.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media. , 2001, The New England journal of medicine.

[12]  Haruo Watanabe,et al.  Use of Antiserum‐Coated Latex Particles for Serotyping Streptococcus pneumoniae , 2001, Microbiology and immunology.

[13]  M. Dosso,et al.  Two-Year Surveillance of Antibiotic Resistance inStreptococcus pneumoniae in Four African Cities , 2001, Antimicrobial Agents and Chemotherapy.

[14]  D. Crook,et al.  Invasive pneumococcal disease in England and Wales: vaccination implications. , 2001, The Journal of infectious diseases.

[15]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[16]  M. Brisson,et al.  Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996–1998 , 2000, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[17]  R. Adegbola,et al.  Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia , 2000, Tropical medicine & international health : TM & IH.

[18]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[19]  G. Siber,et al.  The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Catterall,et al.  Streptococcus pneumoniae , 1999, Thorax.

[21]  I. Jado,et al.  Evolution of Streptococcus pneumoniaeSerotypes and Antibiotic Resistance in Spain: Update (1990 to 1996) , 1998, Journal of Clinical Microbiology.

[22]  R. Steele Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants , 1998, Clinical pediatrics.

[23]  K. Klugman,et al.  Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  G. Rahav,et al.  Invasive Pneumococcal Infections: A Comparison Between Adults and Children , 1997, Medicine.

[25]  S. Ostroff,et al.  Resistance patterns of Streptococcus pneumoniae and Haemophilus influenzae isolates recovered in Egypt from children with pneumonia. The Antimicrobial Resistance Surveillance Study Group. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  G. Gregoriadis Vaccine design: The subunit and adjuvant approach: edited by M.F. Powell and M.J. Newman Plenum, 1995. &145.00 (N. America)/$174.00 (elsewhere) hbk (xliv + 949 pages) ISBN 0 306 44867 X , 1996 .

[27]  S. Obaro,et al.  Fortnightly Review: The pneumococcal problem , 1996 .

[28]  A J Hall,et al.  Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  M. Cetron,et al.  The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. , 1995, The New England journal of medicine.

[30]  Leo Paik,et al.  Outcomes of bacterial miningitis in children: A meta-analysis: Baraff LJ, Lee SI, Schriger DL Pediatr Infect Dis J 12:389–394 May 1993 , 1993 .

[31]  D L Schriger,et al.  Outcomes of bacterial meningitis in children: a meta-analysis. , 1993, The Pediatric infectious disease journal.

[32]  M. Drucker,et al.  Epidemiology of Invasive Childhood Pneumococcal Infections in Israel , 1992 .

[33]  R. Dagan,et al.  Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group. , 1992, JAMA.

[34]  A. Bolmström,et al.  Evaluation of the E-Test for susceptibility testing of pneumococci. , 1992, Diagnostic microbiology and infectious disease.

[35]  A. Shibl,et al.  Surveillance of Streptococcus pneumoniae serotypes in Riyadh and their susceptibility to penicillin and other commonly prescribed antibiotics. , 1992, The Journal of antimicrobial chemotherapy.

[36]  J. Connor,et al.  Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. , 1991, The Pediatric infectious disease journal.

[37]  J. Feeley,et al.  Trans-isolate medium: a new medium for primary culturing and transport of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae , 1984, Journal of clinical microbiology.

[38]  J. C. Parke,et al.  Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. , 1983, The Journal of infectious diseases.

[39]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[40]  H. Koornhof,et al.  Emergence of multiply resistant pneumococci. , 1978, The New England journal of medicine.

[41]  S. Choo,et al.  New pneumococcal vaccines for children. , 2001, Archives of Disease in Childhood.

[42]  G. Siber,et al.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[44]  R. Eby Pneumococcal conjugate vaccines. , 1995, Pharmaceutical biotechnology.

[45]  M. Powell,et al.  Vaccine Design , 1995, Pharmaceutical Biotechnology.

[46]  N. Guirguis,et al.  A suggested vaccine formulation for the control of pneumococcal meningitis in Egypt. , 1990, The Journal of the Egyptian Public Health Association.

[47]  Ali Rh,et al.  A suggested vaccine formulation for the control of pneumococcal meningitis in Egypt. , 1990 .

[48]  J. Robbins,et al.  Bacterial meningitis in Egypt: analysis of CSF isolates from hospital patients in Cairo, 1977-78. , 1983, Bulletin of the World Health Organization.